Project Grant R44DA060643
Award Date
9/15/24
Completion Date
8/31/25
Dollars Obligated
$854K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Allegheny-West, PA 15212, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $800,000 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Biosensics LLC to develop ODALERT, a wearable device for the automatic detection of opioid-induced respiratory arrest. The key products to be delivered under this funding include: Completing the development of the ODALERT sensor, optimizing the battery, and deploying real-time algorithms for respiratory cessation detection. Securing FDA...
The National Institute on Drug Abuse (NIDA) awarded Labsys LLC a $643,948 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The objective is to create a low-cost, painless patch that can monitor medication levels in interstitial fluid to provide real-time insights into the effectiveness of opioid use disorder treatment protocols. The initial Phase I research will focus on...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $800,000 Project Grant to Tenvos Inc., a minority-owned and woman-owned small business, to develop a software-based medical device for detecting opioid use through voice analysis. The proposed solution will integrate into a smartphone app, enabling patients to test for opioid use remotely from home and securely transmit results to their clinicians, thereby improving...
The National Institute on Drug Abuse (NIDA) awarded a $386,452 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant, with a performance period from April 1, 2025 to March 31, 2026, is for the development of a "Rapid Fingerstick Diagnostics for Opioid and Stimulant Use Disorders." This project aims to address the escalating public health crisis of opioid and stimulant use...
The National Science Foundation (NSF) awarded a Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Resilient Lifescience, Inc. for the development and validation of a novel wearable medical device to detect and treat opioid overdose. The $274,964 award, effective March 15, 2024 through December 31, 2024, will fund the development of two key components: 1) a self-contained, patch-based drug delivery platform capable of reliably delivering multiple...
The National Institute on Drug Abuse (NIDA) has awarded a $586,936 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Vitan-Biotech LLC, a minority-owned biotechnology company in Aurora, Colorado. The funding will support the development of a low-cost, disposable urine test strip that can rapidly and quantitatively measure the concentrations of substance use disorder (SUD) medication drugs, such as buprenorphine, methadone, and naltrexone, as well as their...
The National Institute on Drug Abuse (NIDA) awarded a $19,302,777 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Nirsum Laboratories, Inc. to accelerate the development of NRS-033, a novel medication for the treatment of opioid use disorder (OUD). The project aims to advance late-stage chemistry, manufacturing, and controls (CMC), conduct registration-enabling non-clinical studies, establish quality systems, and engage with the FDA to expedite NRS-033 into...
The National Institute on Drug Abuse (NIDA) awarded a $645,594 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Ricovr Healthcare Inc., a minority-owned small business located in Princeton, New Jersey. This Phase I grant will fund the feasibility demonstration of a novel point-of-need (PON) platform device called XALIVA for the accurate and destigmatized detection of recent cannabis use. The key products or services to be delivered include: Proving the...
The National Institute on Drug Abuse (NIDA) awarded a $2,402,305 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Cari Health, Inc. (Doing Business As: Clinical Addiction Recovery Institute) to develop and commercialize a new point-of-care technology to enable individualized methadone dosing for opioid use disorder (OUD) treatment. The project aims to create a device that can quickly evaluate a patient's methadone metabolism rate using a small blood...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $284,040 to the Lieber Institute for Brain Development to conduct research on the molecular mechanisms underlying opioid addiction. The project aims to use integrated single-cell and spatial transcriptomic approaches to map gene expression changes in specific cell populations and projection neurons within the habenula, a key brain region...